European recommendations for the clinical use of HIV drug resistance testing: 2011 update

Anne-Mieke Vandamme; Ricardo J Camacho; Francesca Ceccherini-Silberstein; Andreu de Luca; Lucia Palmisano; Dimitrios Paraskevis; Roger Paredes; Mario Poljak; Jean-Claude Schmit; Vincent Soriano; Hauke Walter; Anders Sönnerborg; European HIV Drug Resistance Guidelines Panel; Jan Gerstoft

European recommendations for the clinical use of HIV drug resistance testing: 2011 update

Anne-Mieke Vandamme, Ricardo J Camacho, Francesca Ceccherini-Silberstein, Andreu de Luca, Lucia Palmisano, Dimitrios Paraskevis, Roger Paredes, Mario Poljak, Jean-Claude Schmit, Vincent Soriano, Hauke Walter, Anders Sönnerborg, European HIV Drug Resistance Guidelines Panel, Jan Gerstoft

116 Citationer (Scopus)

Abstract

The European HIV Drug Resistance Guidelines Panel, established to make recommendations to clinicians and virologists, felt that sufficient new information has become available to warrant an update of its recommendations, explained in both pocket guidelines and this full paper. The Panel makes the following recommendations concerning the indications for resistance testing: for HIV-1 (i) test earliest sample for protease and reverse transcriptase drug resistance in drug-naive patients with acute or chronic infection; (ii) test protease and reverse transcriptase drug resistance at virologic failure, and other drug targets (integrase and envelope) if such drugs were part of the failing regimen; (iii) consider testing for CCR5 tropism at virologic failure or when a change of therapy has to be made in absence of detectable viral load, and in the latter case test DNA or last detectable plasma RNA; (iv) consider testing earliest detectable plasma RNA when a successful nonnucleoside reverse transcriptase inhibitor-containing therapy was inappropriately interrupted; (v) genotype source patient when postexposure prophylaxis is considered; for HIV-2, (vi) consider resistance testing where treatment change is needed after treatment failure. The Panel recommends genotyping in most situations, using updated and clinically evaluated interpretation systems. It is mandatory that laboratories performing HIV resistance tests take part regularly in external quality assurance programs, and that they consider storing samples in situations where resistance testing cannot be performed as recommended. Similarly, it is necessary that HIV clinicians and virologists take part in continuous education and discuss problematic clinical cases. Indeed, resistance test results should be used in the context of all other clinically relevant information for predicting therapy response.

Originalsprog	Engelsk
Tidsskrift	AIDS Reviews
Vol/bind	13
Udgave nummer	2
Sider (fra-til)	77-108
Antal sider	32
ISSN	1139-6121
Status	Udgivet - apr. 2011

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

Vandamme, A-M., Camacho, R. J., Ceccherini-Silberstein, F., de Luca, A., Palmisano, L., Paraskevis, D., Paredes, R., Poljak, M., Schmit, J-C., Soriano, V., Walter, H., Sönnerborg, A., European HIV Drug Resistance Guidelines Panel, & Gerstoft, J. (2011). European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Reviews, 13(2), 77-108.

Vandamme, A-M, Camacho, RJ, Ceccherini-Silberstein, F, de Luca, A, Palmisano, L, Paraskevis, D, Paredes, R, Poljak, M, Schmit, J-C, Soriano, V, Walter, H, Sönnerborg, A, European HIV Drug Resistance Guidelines Panel & Gerstoft, J 2011, 'European recommendations for the clinical use of HIV drug resistance testing: 2011 update', AIDS Reviews, bind 13, nr. 2, s. 77-108.

@article{236cd5c9abd546d8918ab0e0315a899c,

title = "European recommendations for the clinical use of HIV drug resistance testing: 2011 update",

abstract = "The European HIV Drug Resistance Guidelines Panel, established to make recommendations to clinicians and virologists, felt that sufficient new information has become available to warrant an update of its recommendations, explained in both pocket guidelines and this full paper. The Panel makes the following recommendations concerning the indications for resistance testing: for HIV-1 (i) test earliest sample for protease and reverse transcriptase drug resistance in drug-naive patients with acute or chronic infection; (ii) test protease and reverse transcriptase drug resistance at virologic failure, and other drug targets (integrase and envelope) if such drugs were part of the failing regimen; (iii) consider testing for CCR5 tropism at virologic failure or when a change of therapy has to be made in absence of detectable viral load, and in the latter case test DNA or last detectable plasma RNA; (iv) consider testing earliest detectable plasma RNA when a successful nonnucleoside reverse transcriptase inhibitor-containing therapy was inappropriately interrupted; (v) genotype source patient when postexposure prophylaxis is considered; for HIV-2, (vi) consider resistance testing where treatment change is needed after treatment failure. The Panel recommends genotyping in most situations, using updated and clinically evaluated interpretation systems. It is mandatory that laboratories performing HIV resistance tests take part regularly in external quality assurance programs, and that they consider storing samples in situations where resistance testing cannot be performed as recommended. Similarly, it is necessary that HIV clinicians and virologists take part in continuous education and discuss problematic clinical cases. Indeed, resistance test results should be used in the context of all other clinically relevant information for predicting therapy response.",

author = "Anne-Mieke Vandamme and Camacho, {Ricardo J} and Francesca Ceccherini-Silberstein and {de Luca}, Andreu and Lucia Palmisano and Dimitrios Paraskevis and Roger Paredes and Mario Poljak and Jean-Claude Schmit and Vincent Soriano and Hauke Walter and Anders S{\"o}nnerborg and Jan Gerstoft and Jan Gerstoft",

year = "2011",

month = apr,

language = "English",

volume = "13",

pages = "77--108",

journal = "AIDS Reviews",

issn = "1139-6121",

publisher = "PublicacionesPermanyer",

number = "2",

}

TY - JOUR

T1 - European recommendations for the clinical use of HIV drug resistance testing: 2011 update

AU - Vandamme, Anne-Mieke

AU - Camacho, Ricardo J

AU - Ceccherini-Silberstein, Francesca

AU - de Luca, Andreu

AU - Palmisano, Lucia

AU - Paraskevis, Dimitrios

AU - Paredes, Roger

AU - Poljak, Mario

AU - Schmit, Jean-Claude

AU - Soriano, Vincent

AU - Walter, Hauke

AU - Sönnerborg, Anders

AU - European HIV Drug Resistance Guidelines Panel

AU - Gerstoft, Jan

PY - 2011/4

Y1 - 2011/4

N2 - The European HIV Drug Resistance Guidelines Panel, established to make recommendations to clinicians and virologists, felt that sufficient new information has become available to warrant an update of its recommendations, explained in both pocket guidelines and this full paper. The Panel makes the following recommendations concerning the indications for resistance testing: for HIV-1 (i) test earliest sample for protease and reverse transcriptase drug resistance in drug-naive patients with acute or chronic infection; (ii) test protease and reverse transcriptase drug resistance at virologic failure, and other drug targets (integrase and envelope) if such drugs were part of the failing regimen; (iii) consider testing for CCR5 tropism at virologic failure or when a change of therapy has to be made in absence of detectable viral load, and in the latter case test DNA or last detectable plasma RNA; (iv) consider testing earliest detectable plasma RNA when a successful nonnucleoside reverse transcriptase inhibitor-containing therapy was inappropriately interrupted; (v) genotype source patient when postexposure prophylaxis is considered; for HIV-2, (vi) consider resistance testing where treatment change is needed after treatment failure. The Panel recommends genotyping in most situations, using updated and clinically evaluated interpretation systems. It is mandatory that laboratories performing HIV resistance tests take part regularly in external quality assurance programs, and that they consider storing samples in situations where resistance testing cannot be performed as recommended. Similarly, it is necessary that HIV clinicians and virologists take part in continuous education and discuss problematic clinical cases. Indeed, resistance test results should be used in the context of all other clinically relevant information for predicting therapy response.

AB - The European HIV Drug Resistance Guidelines Panel, established to make recommendations to clinicians and virologists, felt that sufficient new information has become available to warrant an update of its recommendations, explained in both pocket guidelines and this full paper. The Panel makes the following recommendations concerning the indications for resistance testing: for HIV-1 (i) test earliest sample for protease and reverse transcriptase drug resistance in drug-naive patients with acute or chronic infection; (ii) test protease and reverse transcriptase drug resistance at virologic failure, and other drug targets (integrase and envelope) if such drugs were part of the failing regimen; (iii) consider testing for CCR5 tropism at virologic failure or when a change of therapy has to be made in absence of detectable viral load, and in the latter case test DNA or last detectable plasma RNA; (iv) consider testing earliest detectable plasma RNA when a successful nonnucleoside reverse transcriptase inhibitor-containing therapy was inappropriately interrupted; (v) genotype source patient when postexposure prophylaxis is considered; for HIV-2, (vi) consider resistance testing where treatment change is needed after treatment failure. The Panel recommends genotyping in most situations, using updated and clinically evaluated interpretation systems. It is mandatory that laboratories performing HIV resistance tests take part regularly in external quality assurance programs, and that they consider storing samples in situations where resistance testing cannot be performed as recommended. Similarly, it is necessary that HIV clinicians and virologists take part in continuous education and discuss problematic clinical cases. Indeed, resistance test results should be used in the context of all other clinically relevant information for predicting therapy response.

M3 - Journal article

SN - 1139-6121

VL - 13

SP - 77

EP - 108

JO - AIDS Reviews

JF - AIDS Reviews

IS - 2

ER -

European recommendations for the clinical use of HIV drug resistance testing: 2011 update

Abstract

FN’s Verdensmål

Fingeraftryk

Citationsformater